A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study-Reference-Cited by-同舟云学术

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

Published:2020-01 Issue:1 Volume:6 Page:
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:A&D Transl Res & Clin Interv

Author:

Hampel Harald¹,Williams Coralie²,Etcheto Adrien²,Goodsaid Federico³,Parmentier Frédéric²,Sallantin Jean⁴,Kaufmann Walter E.⁵⁶,Missling Christopher U.⁵,Afshar Mohammad²

Affiliation:

1. Sorbonne University GRC n° 21, Alzheimer Precision Medicine (APM) AP‐HP, Pitié‐Salpêtrière Hospital Boulevard de l'hôpital Paris France

2. Ariana Pharmaceuticals Paris France

3. Regulatory Pathfinders LLC San Juan Puerto Rico USA

4. Laboratoire d'Intelligence Artificielle LIRMM, CNRS Montpellier France

5. Anavex Life Sciences Corp. New York New York USA

6. Department of Human Genetics Emory University School of Medicine Atlanta Georgia USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12013

Reference64 articles.

1. Alzheimer's disease drug development pipeline: 2018

2. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers;Dong A;Brain J Neurol,2017

3. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer’s disease

4. The importance of endpoint selection: How effective does a drug need to be for success in a clinical trial of a possible Alzheimer’s disease treatment?

5. The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics;Current Pharmaceutical Biotechnology;2024-12

2. The mechanisms, hallmarks, and therapies for brain aging and age-related dementia;Science Bulletin;2024-09

3. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-08

4. The involvement of SigmaR1K142 degradation mediated by ERAD in neural senescence linked with CdCl2 exposure;Journal of Hazardous Materials;2024-07

5. Multi-target drugs for Alzheimer's disease;Trends in Pharmacological Sciences;2024-07